Breaking Finance News

A report released today by Cann about Celgene Corporation (NASDAQ:CELG) ups the target price to $141.00

In a report released on 11/28/2016 Cann increased the stock price target of Celgene Corporation (NASDAQ:CELG) to $141.00 reporting a possible upside of 0.16%.

Previously on 11/28/2016, Vetr Inc. released a statement about Celgene Corporation (NASDAQ:CELG) increased the target price from $0.00 to $125.81. At the time, this indicated a possible upside of 0.04%.

Just yesterday Celgene Corporation (NASDAQ:CELG) traded 0.17% higher at $121.06. Celgene Corporation’s 50-day moving average is $108.41 and its 200-day moving average is $106.51. The last stock price is up 13.66% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 0 shares of CELG traded hands, down from an average trading volume of 4,493,930

Recent Performance Chart

Celgene Corporation (NASDAQ:CELG)

Celgene Corporation has 52 week low of $93.05 and a 52 week high of $127.00 with a PE ratio of 45.98 and has a market capitalization of $0.

In addition to Cann reporting its stock price target, a total of 22 brokerages have issued a ratings update on the company. The average stock price target is $136.82 with 10 brokerages rating the stock a strong buy, 10 brokerages rating the stock a buy, 4 brokerages rating the stock a hold, 1 brokerage rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company's primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company's clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *